Valuation Guided Therapeutics, Inc.
Stocks
GTHP
US40171F5017
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2800 USD | +14.29% |
|
+7.69% | -48.15% |
| 16/06 | Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA | CI |
| 15/05 | Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Guided Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 3.928 | 7.91 | 14.58 | 8.305 | 9.77 | 46.52 |
| Change | - | 101.4% | 84.3% | -43.03% | 17.63% | 376.2% |
| Enterprise Value (EV) 1 | 8.151 | 10.17 | 14.53 | 9.772 | 11.54 | 49.4 |
| Change | - | 24.73% | 42.91% | -32.74% | 18.1% | 328.05% |
| P/E | -7.5x | -3.19x | -1.96x | -2.09x | -3x | -12.7x |
| PBR | -0.29x | -0.64x | -2.44x | -1.22x | -1.24x | -6.1x |
| PEG | - | -0x | 0.1x | 0x | 0.1x | 0.9x |
| Capitalization / Revenue | 38.5x | 97.7x | 1,121x | 84.7x | 1,396x | 60.7x |
| EV / Revenue | 79.9x | 126x | 1,118x | 99.7x | 1,649x | 64.4x |
| EV / EBITDA | -7.91x | -4.31x | -4.36x | -2.83x | -5.5x | -20.9x |
| EV / EBIT | -7.75x | -4.3x | -4.36x | -2.83x | -5.47x | -20.8x |
| EV / FCF | -3.22x | -4.61x | -12.6x | -9.89x | -17.4x | -83.4x |
| FCF Yield | -31% | -21.7% | -7.93% | -10.1% | -5.73% | -1.2% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.04 | -0.1817 | -0.153 | -0.0735 | -0.05 | -0.0427 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.102 | 0.081 | 0.013 | 0.098 | 0.007 | 0.767 |
| EBITDA 1 | -1.031 | -2.361 | -3.329 | -3.448 | -2.099 | -2.362 |
| EBIT 1 | -1.052 | -2.362 | -3.333 | -3.457 | -2.108 | -2.372 |
| Net income 1 | -0.279 | -2.07 | -4.341 | -3.489 | -2.417 | -3.196 |
| Net Debt 1 | 4.223 | 2.256 | -0.05 | 1.467 | 1.771 | 2.876 |
| Reference price 2 | 0.2999 | 0.5802 | 0.3000 | 0.1535 | 0.1500 | 0.5400 |
| Nbr of stocks (in thousands) | 13,096 | 13,634 | 48,596 | 54,105 | 65,131 | 86,154 |
| Announcement Date | 07/04/21 | 30/03/22 | 30/03/23 | 28/03/24 | 31/03/25 | 31/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 2.7Cr | |
| 26.21x | 4.72x | 18.18x | 0.36% | 19TCr | |
| 46.78x | 12.28x | 27.48x | -.--% | 15TCr | |
| 31.53x | - | - | 0.72% | 14TCr | |
| 16.58x | 3.44x | 11.09x | -.--% | 6.71TCr | |
| 33.65x | 7.54x | 23.96x | -.--% | 5.43TCr | |
| 18.42x | 2.12x | 10.91x | 2.85% | 4.46TCr | |
| 25.39x | 5.06x | 17.51x | 0.79% | 3.69TCr | |
| 45.97x | 6.41x | 19.61x | -.--% | 3.72TCr | |
| 14.74x | 1.64x | 9.16x | 0.24% | 2.98TCr | |
| Average | 28.81x | 5.40x | 17.24x | 0.55% | 7.56TCr | |
| Weighted average by Cap. | 31.01x | 6.47x | 19.28x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GTHP Stock
- Valuation Guided Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
